What is Richard Malamut’s share ownership in Pelthos Therapeutics (PTHS) after these awards?

After the reported grants, Malamut holds 28,012 shares of Common Stock directly and 1,040 shares indirectly. The indirect shares are jointly held with his spouse, reflecting shared ownership outside his sole name.

Board member Richard Malamut logs revised RSU stock awards at Pelthos (PTHS)

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

4/A

Rhea-AI Filing Summary

Malamut Richard reported acquisition or exercise transactions in this Form 4 filing.

Pelthos Therapeutics Inc. director Richard Malamut filed an amended Form 4 to reclassify previously reported equity awards. The filing reports grants of 6,450, 19,108, and 2,454 shares of Common Stock at a price of $0.00 per share, reflecting restricted stock units (RSUs) issued under the company’s 2023 Equity Incentive Plan.

Each RSU represents the right to receive one share of Common Stock and vests in equal quarterly installments over three years, contingent on continued board service. The share amounts have been adjusted for the company’s 1-for-10 reverse stock split effective July 1, 2025. Following these awards, Malamut is shown with 28,012 directly held shares and an additional 1,040 shares indirectly held jointly with his spouse.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Malamut Richard

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	2,454	$0.00	--
Grant/Award	Common Stock	19,108	$0.00	--
Grant/Award	Common Stock	6,450	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 8,904 shares (Direct); Common Stock — 1,040 shares (Indirect, Jointly held with spouse)

Footnotes (1)

From June 18, 2024 to July 7, 2025, the reporting person filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the "Original Form 4s"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I. The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary. Amounts have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

Key Figures

RSU-related stock grant: 6,450 shares RSU-related stock grant: 19,108 shares RSU-related stock grant: 2,454 shares +5 more

8 metrics

RSU-related stock grant 6,450 shares Common Stock award dated June 14, 2024

RSU-related stock grant 19,108 shares Common Stock award dated July 2, 2025

RSU-related stock grant 2,454 shares Common Stock award dated November 13, 2025

Grant price $0.00 per share All reported Common Stock awards

Direct holdings after award 28,012 shares Common Stock directly held after July 2, 2025 grant

Indirect joint holdings 1,040 shares Common Stock jointly held with spouse as of June 14, 2024

Reverse stock split ratio 1-for-10 Effective July 1, 2025

RSU vesting span 3 years Quarterly vesting schedule for RSUs

Key Terms

restricted stock units, 2023 Equity Incentive Plan, reverse stock split, Form 4 amendment, +1 more

5 terms

restricted stock units financial

"issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2023 Equity Incentive Plan financial

"RSUs granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan"

reverse stock split financial

"Amounts have been adjusted to reflect the 1-for-10 reverse stock split effected"

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

Form 4 amendment regulatory

"This Form 4 amendment (this "Amendment") is being filed to amend"

board of directors financial

"received as compensation for the reporting person's service as a member of the Issuer's board of directors"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

Form 4 Insider Transactions: What Each Field Means →

04/01/2026 - 05:44 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malamut Richard

(Last)

(First)

(Middle)

C/O PELTHOS THERAPEUTICS INC.

4020 STIRRUP CREEK DRIVE, SUITE 110

(Street)

DURHAM

NORTH CAROLINA

27703

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pelthos Therapeutics Inc. [ PTHS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/14/2024

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
07/07/2025

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock⁽¹⁾	06/14/2024		A		6,450⁽²⁾	A	$0⁽²⁾	6,450⁽³⁾	D
Common Stock⁽¹⁾	11/13/2025		A		2,454⁽²⁾	A	$0⁽²⁾	8,904⁽³⁾	D
Common Stock⁽¹⁾	07/02/2025		A		19,108⁽²⁾	A	$0⁽²⁾	28,012	D
Common Stock								1,040⁽³⁾	I	Jointly held with spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. From June 18, 2024 to July 7, 2025, the reporting person filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the "Original Form 4s"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I.

2. The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

3. Amounts have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Francis Knuettel II, by power of attorney	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Pelthos Therapeutics (PTHS) director Richard Malamut report in this Form 4/A?

He reported equity awards of Common Stock tied to prior RSU grants. The amendment moves these RSUs from derivative reporting to direct stock reporting, with no cash purchases or sales disclosed in this filing.

How many Pelthos Therapeutics (PTHS) shares were granted to Richard Malamut?

The filing shows grants of 6,450, 19,108, and 2,454 shares of Common Stock. All were recorded at a price of $0.00 per share, reflecting compensation rather than market transactions.

How do the Pelthos Therapeutics (PTHS) RSUs for Richard Malamut vest?

The RSUs vest in equal quarterly installments over three years. Vesting continues only while Malamut remains in service on the Pelthos Therapeutics board of directors during each applicable vesting date.

What is the impact of the reverse stock split mentioned in the Pelthos (PTHS) filing?

Share amounts were adjusted for a 1-for-10 reverse stock split effective July 1, 2025. This reduced the number of shares reported but increased the per-share value proportionally, leaving the underlying economic interest unchanged.

Are the Pelthos Therapeutics (PTHS) RSU grants open-market purchases or sales?

No, they are compensatory awards. The RSUs were granted under the 2023 Equity Incentive Plan for board service and settled in shares at $0.00 per share, rather than through open-market buying or selling.